🇪🇺 Pumarix™ in European Union

EMA authorised Pumarix™ on 4 March 2011

Marketing authorisation

EMA — authorised 4 March 2011

  • Application: EMEA/H/C/001212
  • Marketing authorisation holder: GlaxoSmithKline Biologicals S.A.
  • Local brand name: Pumarix
  • Indication: Prophylaxis of influenza in an officially declared pandemic situation. Pandemic-influenza vaccine should be used in accordance with official guidance.
  • Pathway: exceptional circumstances
  • Status: withdrawn

Read official source →

Frequently asked questions

Is Pumarix™ approved in European Union?

Yes. EMA authorised it on 4 March 2011.

Who is the marketing authorisation holder for Pumarix™ in European Union?

GlaxoSmithKline Biologicals S.A. holds the EU marketing authorisation.